Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-08-17
2009-02-17
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730
Reexamination Certificate
active
07491393
ABSTRACT:
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5116964 (1992-05-01), Capon
patent: 5304635 (1994-04-01), Imam
patent: 5434131 (1995-07-01), Linsley
patent: 5521288 (1996-05-01), Linsley
patent: 5580756 (1996-12-01), Linsley
patent: 5747034 (1998-05-01), De Boer
patent: 5770197 (1998-06-01), Linsley
patent: 5844095 (1998-12-01), Linsley
patent: 5885579 (1999-03-01), Linsley
patent: 6051228 (2000-04-01), Aruffo
patent: 6113898 (2000-09-01), Anderson
patent: 6162432 (2000-12-01), Wallner
patent: 6709654 (2004-03-01), Anderson
patent: 6893638 (2005-05-01), Anderson
patent: 7153508 (2006-12-01), Anderson
patent: 7192585 (2007-03-01), Anderson
patent: 0 173 494 (1986-03-01), None
patent: 0 194 276 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: 87/01131 (1987-02-01), None
patent: 90/07861 (1990-07-01), None
patent: 92/06193 (1992-04-01), None
patent: 93/02108 (1993-02-01), None
patent: 93/09812 (1993-05-01), None
patent: 93/20210 (1993-10-01), None
patent: 94/01547 (1994-01-01), None
patent: 94/28912 (1994-12-01), None
patent: 95/04081 (1995-02-01), None
patent: 95/06481 (1995-03-01), None
patent: 95/06666 (1995-03-01), None
patent: 95/22619 (1995-08-01), None
patent: 95/33770 (1995-12-01), None
patent: 96/40878 (1996-12-01), None
patent: 98/19706 (1998-05-01), None
Alegre et al, “Effect of single amino acid mutation on the activating and immunosuppressive properties of a “Humanized” OKT3 monoclonal antibody,”J. Immunol., 1992, 148:3461-3468.
Armitage et al., “Molecular and biologial characterization of a murine ligand for CD40,”Nature, 1992, 357:80-82.
Azuma et al., “CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small resting T lymphocytes,”J. Exp. Med., 1992, 175:353-360.
Azuma et al., “Functional expression of B7/BB1 on activated T lymphocytes,”J. Exp. Med., 1992, 177:845-850.
Azuma et al., “B7 antigen is a second ligand for CTLA-4 and CD28,”Nature, 1993, 366:76-79.
Barbas et al., “Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity,”Proc. Natl. Acad. Sci. USA, 1992, 89:10164-10168.
Ben-Nun et al., “The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis,”Eur. J. Immunol., 1981, 11:195-199.
Blazar et al., “Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells,”J. Immunol., 1996, 157:3250-3259.
Boussiotis et al., “Activated human B lymphocytes express three CTLA-4 counter-receptors that co-stimulate T-Cell activation,”Proc. Natl. Acad. Sci., USA, 1993, 90:11059-11063.
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature, 1989, 337:525-531.
Chen et al., “Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes,”J. Immunol., 1994, 152 (5):2105-2114.
Cohen, “Mounting a targeted strike on unwanted immune responses,”Science, 1992, 257:751.
Cohen, “New protein steals the show as ‘costimulator’ of T cells,”Science, 1993, 262:844-845.
Daikh et al., “The CD28-B7 costimulatory pathway and its role in autoimmune disease,”J. Leukos. Biol., 1997, 62(2):156-162.
Dautigny et al., “Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid,”FEBS Lett., 1985, 188(1):33-36.
Davila-Bloom et al., “Monoclonal antibody studies of the antigenic determinants of human plasma retinol-binding protein,”J. Nutr. Biochem, 1990, 1(5):262-271 (abstract only).
De Boer et al., “Functional characterization of a novel anti-B7 monoclonal antibody,”Eur. J. Immunol., 1992, 22:3071-3075.
Delabie et al., “The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines,”Blood, 1993, 82:2845-52.
Dermer et al., “Another anniversary for the war on cancer,”Biotechnology, 1994, 12:320.
Dillman et al., “Antibodies as cytotoxic therapy,”J. Clin. Oncol., 1994, 12:1497-1515.
Durie et al., “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40,”Science, 1993, 261:1328-1330.
Durie et al., “The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease,”Res. Immunol., 1994, 145(3):200-205 & 244-249.
Engel et al., “The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen,”Blood, 1994, 84:1402-1407.
Falini et al., “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin,”Lancet, 1992, 339:1195-1196.
Freeman et al., “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation,”Science, 1993, 262:909-911.
Freeman et al., “CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation,”J. Immunol., 1992, 149:3795-3801.
Freeman et al., “Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7,”J. Exp. Med., 1991, 174:625-631.
Freeman et al., “Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice,”Science, 1993, 262:907-909.
Freeman et al., “B7, a new member of the lg superfamily with unique expression on activated and neoplastic B cells,”J. Immunol., 1989, 143:2714-2722.
Geenen et al., “Multiple ways to cellular immune tolerance,”Immunol. Today, 1993, 14:573.
Gerritse et al., “CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis,”Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
Gimmi et al., “Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation,”Proc. Natl. Acad. Sci. USA, 1993, 90:6586-6590.
Gottlieb et al., “Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody,”J. Am. Acad. Dermatol., 2002, 47:692-700.
Gottlieb et al., “Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis,”J. Invest. Dermatol., 2000, 114:840, Abstract No. 546.
Gottlieb et al., “Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab in patients with moderate to severe plaque psoriasis,”Clin. Immunol., 2004, 111:28-37.
Gribben et al.,
Anderson Darrell R.
Brams Peter
Hanna Nabil
Biogen Idec Inc.
Gambel Phillip
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Methods of inhibiting IL-2 production by T cells by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting IL-2 production by T cells by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting IL-2 production by T cells by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4082678